Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Introduction Cognitive impairment is a common consequence after stroke. Intermittent theta burst stimulation (iTBS) has emerged as a promising cognitive therapy. However, traditional iTBS typically ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...
Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...
A healthy Nordic diet, high in dietary fibre from whole grains, fruits and vegetables but with a small percentage of ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Dimerix completes patient enrolment in ACTION3 phase 3 trial of DMX-200 to treat focal segmental glomerulosclerosis: Melbourne, Australia Tuesday, December 16, 2025, 18:00 Hrs [IS ...
PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy ...
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback